Eikon Therapeutics IPO

Eikon Therapeutics, based in Hayward, Calif., was founded in 2019 by Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian. In 2014, Betzig shared the Nobel Prize in Chemistry. Robert Perlmutter is the company’s chairman and CEO. Eikon, which was last valued on January 2022 at $3.1 billion, is a drug discovery and development company that leverages superior engineering and high-performance computing to analyze single molecule protein behavior in living cells.

In January 2022, the company raised $525 million in Series B financing led by more than a dozen investors including T. Rowe Price Associates, Inc., Canada Pension Plan Investment Board, UC Investments, Soros Capital and Schroders Capital.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Eikon Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Eikon Therapeutics's ticker symbol?

Eikon Therapeutics does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

What is Eikon Therapeutics's stock price?

The stock price for Eikon Therapeutics will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Who are Eikon Therapeutics's major investors?

General Catalyst
Lux Capital
AME Cloud Ventures
Horizons Ventures
Innovation Endeavors
The Column Group

Eikon Therapeutics Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
5/16/2023 Series C $535MM raised $XXX.XX $XXX.XX
1/6/2022 Series B $525MM raised $XXX.XX $XXX.XX
5/5/2021 Series A and A-1 $150.54MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Eikon Therapeutics

Forge green plus iconForge green minus icon

What is Eikon Therapeutics funding to date?

Eikon Therapeutics has raised $1.21B with the following series:
$150.54MM raised for Series A and A-1,$525MM raised for Series B,$535MM raised for Series C.
Forge green plus iconForge green minus icon

When was Eikon Therapeutics founded?

Eikon Therapeutics was founded in 2019.
Forge green plus iconForge green minus icon

Can you invest in Eikon Therapeutics?

Eikon Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Eikon Therapeutics share pre-IPO?

If you own Eikon Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Eikon Therapeutics a publicly traded company?

Eikon Therapeutics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Other companies like Eikon Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Updated on: Feb 21, 2023